Can You Take Finasteride Forever? What to Know Long-Term

Finasteride has been studied continuously for over a decade in large groups of men, and the data consistently show that its hair-preserving and prostate-shrinking effects hold up across that entire span without fading. There is no built-in expiration date on the prescription. Most dermatologists and urologists treat it as an indefinite medication, much like a statin or blood-pressure drug, because the condition it manages (whether hair loss or an enlarged prostate) will resume if you stop. That said, “can” and “should” are different questions, and the long-term picture involves trade-offs worth understanding before you commit to years of daily pills.

What Ten-Year Data Actually Show

The strongest evidence for truly long-haul finasteride use comes from Japanese studies tracking men with androgenetic alopecia for a full decade on 1 mg daily. In a cohort of 532 men, roughly 91% showed measurable improvement at the ten-year mark, and over 99% had at least maintained their baseline hair status, meaning the drug prevented further visible loss in nearly everyone who stuck with it.¹ Those results were replicated across three separate large-scale Japanese investigations, all of which landed in the same ballpark.²

A notable pattern emerged in these studies: men who showed little change after the first year often continued to improve in subsequent years. The drug’s effect did not plateau or weaken over time. Instead, a sizeable group of initial “non-responders” crossed into the improvement category during years two through ten.³ Younger men and those who started treatment at an earlier stage of hair loss tended to see the most benefit, but even men who began with more advanced thinning held ground.²

For men taking finasteride at the higher 5 mg dose for an enlarged prostate, a separate long-term trial (the MTOPS study) found that the drug significantly slowed clinical progression compared to placebo in men whose prostates were 30 ml or larger. Over the study period, about 88% of finasteride-treated men with larger prostates avoided progression, compared to roughly 78% on placebo.⁴ Long-term treatment also shrank prostate volume by about 25% across all prostate sizes.⁵

What Happens If You Stop

This is the part that catches many people off guard. Finasteride does not cure androgenetic alopecia; it suppresses the hormonal driver. When you stop, that driver comes back. A study tracking men who discontinued after sustained use found that within 30 months of stopping, 94% of previously healthy terminal hairs miniaturized and became unproductive.⁶ The researchers described this as a “rebound effect” and characterized the maintained follicles as effectively “finasteride-dependent.”

The timeline is worth noting. Hair did not begin falling out immediately. Because a hair cycle initiated while on the drug takes roughly a year to complete, visible shedding and miniaturization mostly occurred between 12 and 30 months after stopping. So you will not notice dramatic changes in the first few months off the medication, which can create a false sense that you are fine without it. The loss catches up later. This rebound dynamic is the primary reason doctors frame finasteride as a long-term or indefinite commitment for hair loss.

Sexual Side Effects Over Years of Use

Sexual side effects are the most commonly discussed concern with finasteride, and the data on them are both reassuring and complicated. Across placebo-controlled trials of the 1 mg hair-loss dose, sexual adverse events were reported by roughly 2–7% of treated men compared to 1–4% on placebo.⁷ The most common complaints are reduced libido, difficulty achieving or maintaining erections, and decreased ejaculate volume. In the majority of men who experience these effects, symptoms are mild and resolve after stopping the drug.

Where it gets more complicated is a small subset of men who report that sexual, neuropsychiatric, or physical symptoms persist for months or longer after discontinuation, a pattern that has come to be called post-finasteride syndrome. Research into this group has found measurable changes in neurosteroid levels in both spinal fluid and blood, including lower levels of dihydrotestosterone and altered levels of several other hormones that influence nervous system function.⁸ One small study found that all 16 post-finasteride patients examined had erectile dysfunction, and half met criteria for major depressive disorder, with objective nerve-conduction abnormalities documented for the first time.⁹

The honest state of the science here is unsettled. Post-finasteride syndrome is recognized as a real clinical entity by the researchers studying it, and it has prompted regulatory label updates in several countries.¹⁰ But the published studies of persistent symptoms involve small numbers of self-selected patients, making it difficult to estimate how common it truly is. The gap between large clinical trials showing low and reversible side-effect rates and smaller case-series studies documenting persistent neurosteroid changes is the central tension in the finasteride safety debate, and no one has fully resolved it yet.

The Mental Health Question

Reports of depression and suicidal ideation in men taking finasteride have drawn significant attention and generated conflicting study results. An analysis of the FDA’s adverse-event reporting system found that the likelihood of suicidal ideation being reported in people taking oral finasteride was elevated in both the 2013–2018 and 2019–2023 periods.¹¹ But spontaneous adverse-event databases have well-known limitations: they capture reports, not confirmed causation, and reporting rates can be influenced by media coverage and patient awareness.

Studies using different methods have pointed in the opposite direction. A large cohort analysis from the UK Biobank, combined with a genetic-analysis technique designed to test for causal relationships, concluded that finasteride use was not significantly associated with depression or suicide events.¹² A nationwide cohort study comparing finasteride and dutasteride users found that the association with suicidal risk was not statistically significant in men without a psychiatric history. In men with a history of mood disorders, there was a modestly elevated risk, though the finding was right at the edge of statistical significance.¹³

The practical takeaway: if you have a history of depression or mood disorders, the conversation with your doctor about long-term finasteride deserves more weight. For men without that history, the large-scale data do not show a clear psychiatric risk, but the question has not been definitively closed.

PSA Monitoring and Prostate Cancer Screening

Finasteride lowers prostate-specific antigen (PSA) levels by about 50% after six months of use, a reduction that persists as long as you keep taking it.¹⁴ This creates a practical wrinkle for cancer screening. If your doctor does not know you are on finasteride and interprets a PSA result at face value, a genuinely elevated number might look normal. In a large prevention trial, men on finasteride who did not have cancer showed a slow annual PSA decline of about 2% per year after the initial drop, while men on placebo showed a 3% annual increase. Men who developed cancer, however, showed rising PSA in both groups, with high-grade disease producing steeper increases.¹⁵

The standard clinical workaround is simple: if you are on finasteride, your doctor should roughly double any PSA reading to estimate what it would be without the drug. Any sustained rise in PSA while on finasteride, even if the absolute number looks low, should be taken seriously. Over half of urologists surveyed in one cross-sectional study expressed concern about 5-alpha reductase inhibitors masking early prostate cancer.¹⁴ Make sure every doctor ordering blood work on you knows you take it.

Bones, Liver, and Metabolic Health

Because finasteride suppresses dihydrotestosterone throughout the body, not just in the scalp, there is a reasonable question about what prolonged systemic DHT suppression does to other organs. The evidence is mixed depending on which organ system you look at.

For bones, the news is good. A four-year placebo-controlled trial found no difference in bone mineral density between finasteride and placebo groups.¹⁶ A separate study in healthy young men also found that suppressing DHT with finasteride (or dutasteride) did not significantly affect bone density, lipid levels, or hemoglobin.¹⁷

For the liver specifically, a study examining cholesterol effects found that finasteride did not affect standard markers of liver damage or a newer molecular marker of liver toxicity.¹⁸ However, a broader review has raised concerns that chronic DHT suppression could contribute to non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and possible kidney effects by creating a form of tissue-specific androgen deficiency.¹⁹ These concerns are based on the known biological roles of DHT in those tissues and on emerging (mostly preclinical or observational) data, not on large-scale trials designed to test those outcomes directly. They represent plausible theoretical risks that have not yet been confirmed or refuted with definitive long-term human studies.

One intriguing counterpoint: in mouse models of heart disease, finasteride markedly improved cardiac function, reduced heart enlargement and scarring, and even improved survival after prolonged stress on the heart, in both male and female animals.²⁰ Whether that translates to meaningful cardiovascular benefits in humans remains to be seen, but it is a reminder that the systemic effects of DHT suppression are not uniformly harmful.

Fertility Considerations

If you are trying to conceive, this is one area where the long-term picture demands attention. Even at the low 1 mg dose, finasteride can significantly reduce sperm counts in some men. A study of infertile men who had been taking finasteride found that after stopping the drug, sperm counts increased by an average of nearly 12-fold. Among those with very low counts while on the drug, over half recovered to normal levels after discontinuation.²¹ No man in the study saw his count go down after stopping, which is reassuring about reversibility. But the size of the suppression while on the drug was substantial.

A systematic review of both human and animal evidence concluded that finasteride was associated with several types of reproductive harm, including damage to the epididymis (the structure where sperm mature), erectile dysfunction, reduced libido, and decreased semen volume.²² For men who plan to start a family in the near future, most specialists recommend pausing finasteride and waiting several months for sperm parameters to recover. For men not actively trying to conceive, the effect on sperm counts is generally reversible and not a reason to avoid the drug, but it is something to plan around.

Topical Finasteride as a Lower-Risk Alternative

One of the more interesting developments for men worried about side effects from indefinite use is the topical formulation. By applying finasteride directly to the scalp, you get local DHT suppression with much less systemic absorption. A phase III trial found that topical finasteride spray produced hair-count improvements similar to the oral pill, while maximum blood levels of the drug were over 100 times lower. Serum DHT dropped by about 35% with topical application versus about 56% with the oral version.²³

A year-long real-world study of topical finasteride 0.25% found significant increases in hair density in both the crown and temple regions, with no systemic sexual or mood side effects reported. Mild scalp irritation occurred in about 7% of users.²⁴ The topical route is not yet as well studied over a full decade as the oral pill, so the very-long-term picture is less clear. But for men who want to continue using finasteride indefinitely while minimizing the chance of sexual or systemic side effects, a topical formulation is an increasingly well-supported option.

Dutasteride and Combination Therapy

For men who have been on finasteride for years but feel their results are stalling, dutasteride is the usual next step. Dutasteride blocks both types of the 5-alpha reductase enzyme, whereas finasteride blocks only one. A multicentre chart review found that dutasteride-treated patients showed about twice the improvement in hair growth compared to finasteride when both were used at their recommended doses.²⁵ An 18-month head-to-head trial confirmed the advantage: terminal hair density increased about 9% with finasteride compared to about 17% with dutasteride, and marked improvement was seen in roughly 57% versus 77% of patients respectively. Sexual side effects were numerically higher with dutasteride but not statistically different, and no patient in the study stopped treatment because of them.²⁶

Combination approaches also deserve mention. A retrospective evaluation of over 500 men taking low-dose oral minoxidil together with finasteride found that 92% achieved stable or improved outcomes at 12 months, with nearly 58% showing clear regrowth.²⁷ These combination regimens are becoming a standard approach in clinics managing men who want to maintain results over many years, particularly those with more advanced loss.

Finasteride in Women

While the vast majority of long-term data involves men, finasteride sees off-label use in women with pattern hair loss, typically postmenopausal women or those on reliable contraception (finasteride can cause birth defects in male fetuses). Available evidence suggests real efficacy: in studies of postmenopausal women, about 81–82% showed improvement in hair thickness or density over several years of treatment, with phototrichogram data showing roughly 19% increased hair density and 9% increased hair diameter compared to baseline.²⁸ However, the evidence base for women is far thinner than for men, and true long-term safety data spanning a decade or more simply do not exist in this population. Women considering indefinite use face greater uncertainty than men about what the very long run looks like.

How the Drug Actually Works and Why That Matters for Duration

Finasteride blocks the enzyme that converts testosterone into dihydrotestosterone. In the scalp, that conversion is what drives follicle miniaturization and eventual hair loss. Studies measuring hormone levels directly in scalp tissue and blood confirm that the drug significantly reduces the ratio of DHT to testosterone in both locations.²⁹ The oral 1 mg dose typically reduces circulating DHT by about 60–70%.³⁰

This mechanism is why the drug must be taken continuously. Finasteride does not alter the underlying genetic programming that makes your follicles sensitive to DHT. It does not permanently change enzyme levels. It temporarily suppresses them, and once the drug clears your system, DHT production returns to its previous level. The condition is still there; you are just chemically managing it. That is fundamentally similar to how blood pressure medication or thyroid replacement works: the drug treats the symptom continuously, not the root cause once.

Understanding this removes some of the anxiety around the phrase “taking it forever.” You are not accumulating a drug in your body in some dangerous way. Finasteride has a short half-life of roughly six to eight hours. Each pill is metabolized and excreted, and the next one picks up where the last left off. The long-term question is not about drug accumulation but about whether decades of lowered DHT levels create problems that shorter-term use would not. That question, as the metabolic and systemic safety sections above illustrate, is still being studied. But the drug itself does not build up over time.

The Nocebo Effect and Informed Consent

One factor that complicates the side-effect conversation is the nocebo effect, which is the tendency to experience symptoms you have been warned about. Several analyses of finasteride trials have noted that sexual side-effect rates are higher in studies where patients were explicitly told about sexual risks beforehand, compared to trials where they were not. The gap between finasteride and placebo arms for sexual complaints is often narrow enough that expectations play a measurable role.

This does not mean the side effects are imaginary. Placebo-controlled data consistently show a real, if modest, excess of sexual complaints in finasteride groups. But it does mean that reading alarming internet forums before starting the medication may genuinely increase your chance of experiencing problems, a real physiological effect mediated by anxiety and expectation rather than by the drug’s chemistry. The challenge for doctors is threading the needle between ethically informing you of real risks and inadvertently priming you to develop symptoms. If your prescriber seems to downplay side effects, that may be a deliberate clinical strategy rather than ignorance of the literature.